Connect with us


New treatment pathway discovered for persistent Lyme disease symptoms – Study, ET HealthWorld



Researchers find new treatment path for lasting Lyme disease symptoms, ET HealthWorld

Tulane University researchers have made a groundbreaking discovery in the treatment of persistent neurological symptoms associated with Lyme disease. The study, published in Frontiers in Immunology, offers hope to patients who continue to suffer from the bacterial infection even after antibiotic treatment. Lyme disease, caused by Borrelia burgdorferi bacteria spread through tick bites, can lead to various symptoms affecting the central and peripheral nervous systems. While most cases can be treated with medications, some individuals experience ongoing symptoms like memory loss, exhaustion, and pain, known as post-treatment Lyme disease syndrome.

Principal investigator Geetha Parthasarathy, PhD, found that fibroblast growth factor receptor inhibitors, previously studied in cancer treatment, can significantly reduce inflammation and cell death in brain and nerve tissue infected with Borrelia burgdorferi. This discovery suggests that targeting FGFR pathways may offer a new therapeutic approach to addressing persistent neuroinflammation in patients with post-treatment Lyme disease syndrome.

Dr. Parthasarathy stated, “Our findings open the door to new research approaches that can help us support patients suffering from the lasting effects of Lyme disease. By focusing on the underlying inflammation contributing to these symptoms, we aim to develop treatments that can enhance the quality of life for those affected by this debilitating condition.”

This research provides a promising avenue for the development of treatments that target the root cause of persistent neurological symptoms in Lyme disease patients. The study sheds light on a potential new therapeutic strategy that could improve the lives of individuals experiencing post-treatment Lyme disease syndrome.

Click to comment

You must be logged in to post a comment Login

Leave a Reply